查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969410

抗生素抗藥性市場：依產品類型、病原體類型、感染疾病類型和最終用途分類－2026-2030年全球預測

Antibiotic Resistance Market by Offering, Pathogen Type, Infection Type, End Use - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年抗生素抗藥性市場價值為 75.1 億美元，預計到 2025 年將成長至 79.6 億美元，年複合成長率為 6.12%，到 2030 年將達到 107.3 億美元。

主要市場統計數據
基準年 2024 75.1億美元
預計年份：2025年 79.6億美元
預測年份 2030 107.3億美元
複合年成長率 (%) 6.12%

抗生素抗藥性問題日益嚴峻，正在醫療保健系統中蔓延，這是全球相關人員面臨的關鍵問題。

隨著抗生素抗藥性以前所未有的速度加速發展，全球醫療衛生系統正面臨日益嚴峻的危機。曾經對標準療法敏感的病原體正在進化出新的機制，以逃避曾經可靠的藥物武器。結果，病患住院時間延長、醫療成本飆升、死亡率上升，這些都給各國帶來了沉重的負擔。在此背景下，理解科學創新、政策改革和臨床實踐之間的相互作用至關重要。

揭示抗生素開發平臺的變革性轉變：法規結構和全球衛生政策正在重塑治療策略和市場現實。

科學突破、監管調整和不斷變化的資金籌措機制的協同作用正在重塑抗生素領域的模式。近年來，適應性試驗設計加速了候選藥物的篩檢，而人工智慧和機器學習平台則簡化了標靶辨識和先導化合物最佳化流程。同時，監管機構正在推出獎勵以促進新藥研發，並強調轉向基於價值的核准途徑和快速審查模式轉移。

評估美國關稅政策在 2025 年對抗生素供應鏈、研發投資和市場進入。

美國2025年實施的關稅措施為抗生素供應鏈格局帶來了新的變數。關鍵中間體、最終製劑和主要原料關稅的提高波及整個生產流程，推高了單位成本，擠壓了利潤空間。成本基數的擴大促使採購部門重新談判供應商契約，並探索替代採購方式，從而改變了現有的供應鏈關係。

透過明確藥物類別、病原體類型、傳染性變異株和最終用途類別的市場細分，我們旨在確定目標機會和策略挑戰。

一個穩健的細分框架突顯了戰略潛力，並明確指出了抗藥性挑戰的領域。從藥物類別來看，Aminoglycosides對革蘭氏陰性菌具有強效殺菌活性，但其治療指數較窄，需密切監測。頭孢菌素類抗菌頻譜廣，但在院內感染中抗藥性不斷上升。聯合治療因其對多重抗藥性細菌的協同作用而日益重要，而醣肽儘管存在腎毒性的擔憂，仍然是治療方法嚴重革蘭氏陽性病菌感染的主要藥物。Oxazolidinone、磺胺類藥物和四環黴素在作用機轉和安全性方面各有特點，需要根據具體情況制定個人化的治療方案。

為了突顯成長要素和新興挑戰，我們將分析美洲、歐洲、中東和非洲以及亞太地區的區域市場動態。

區域差異持續影響抗生素抗藥性的動態變化和策略重點。在美洲，完善的監管途徑和報銷機制支持先進治療創新技術的應用。然而，門診環境中頻譜抗生素的廣泛使用正在加速抗藥性表現型的出現，導致更嚴格的合理用藥指南和處方箋限制。同時，拉丁美洲市場面臨不穩定的供應鏈和監管執法不力的問題，加劇了區域高風險病原體的出現。

透過分析領先的製藥公司和新興的抗生素研發和商業化創新者，闡明競爭策略、產品系列和合作網路。

老牌製藥公司憑藉著多元化的產品系列和廣泛的全球佈局，不斷鞏固其在抗生素市場的地位。這些行業領導者優先考慮在現有藥物類別的基礎上進行漸進式改進，同時投資於噬菌體療法和抗菌肽等突破性治療方法。同時，新興生技公司則專注於精準標靶作用機制，並利用先進的篩檢平台發現不易產生抗藥性的新型骨架，從而在市場中佔有一席之地。

為產業領導者提供的實用策略建議：促進合理使用抗生素、鼓勵創新、加強合作、降低抗藥性風險。

產業領導者必須採取多管齊下的策略方法，才能有效應對抗生素抗藥性所帶來的挑戰。首先，加強合理使用抗菌藥物是首要任務。這包括將決策支援工具整合到電子健康記錄中，以指導處方醫生選擇最佳劑量方案和窄頻譜藥物。其次，企業應加速早期藥物研發平台的投資，優先開發能夠繞過現有抗藥性機制的新標靶和創新治療方法。

嚴謹的調查方法詳情：為了確保分析的穩健性，我們採用了調查方法。

本報告基於嚴謹的多層次調查方法，旨在確保分析的可靠性和事實的準確性。主要研究工作包括對30多位高階主管進行深入訪談，其中包括製藥公司高階主管、臨床微生物學家、政策顧問以及感染疾病控制領域的關鍵意見領袖（KOL）。這些訪談提供了關於策略重點、營運挑戰和市場預測的定性背景資訊。

我們將整合抗生素抗藥性惡化、市場轉型和策略路徑的關鍵見解，使決策者能夠獲得清晰的見解，從而支持積極主動的規劃。

抗生素抗藥性已超越單純的臨床問題，成為政策、經濟和公共衛生交叉領域的嚴峻挑戰。在這種不斷變化的情況下，相關人員需要採取綜合策略。具體而言，該策略需要結合創新研究、快速監管反應和健全的控制系統，以加速新治療方法的研發，同時保障現有治療方法的有效性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 抗生素抗藥性市場：依產品/服務分類

  • 聯合治療
  • 藥物
    • Aminoglycosides
    • BETA-內醯胺
    • Fluoroquinolones
    • 醣肽
    • 大環內酯類
    • Oxazolidinone系列
    • 多粘菌素
    • 磺胺類藥物藥物
    • 四環黴素
  • 免疫調節劑
  • 單株抗體
  • 噬菌體療法

第9章：按病原體類型分類的抗生素抗藥性市場

  • 鮑曼鮑氏不動桿菌
  • 大腸桿菌（E. coli）
  • 肺炎克雷伯菌
  • 銅綠假單胞菌
  • 金黃色葡萄球菌
  • 肺炎鏈球菌

第10章：依感染疾病類型分類的抗生素抗藥性市場

  • 急性細菌性皮膚及皮膚組織感染疾病（ABSSSI）
  • 血液感染疾病（BSI）
  • 艱難梭菌感染疾病（CDI）
  • 社區型細菌性肺炎（CABP）
  • 複雜性尿道感染（cUTI）

第11章 抗生素抗藥性市場：依最終用途分類

  • 門診部
  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第12章：抗生素抗藥性市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：抗生素抗藥性市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：抗生素抗藥性市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國抗生素抗藥性市場

第16章：中國抗生素抗藥性市場

第17章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Basilea Pharmaceutica Ltd
  • bioMerieux SA
  • Cipla Limited
  • Cumberland Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Innoviva, Inc.
  • Johnson & Johnson Services, Inc.
  • Novo Holdings A/S
  • Pfizer Inc.
  • Sandoz AG
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 7.51 billion in 2024 and is projected to grow to USD 7.96 billion in 2025, with a CAGR of 6.12%, reaching USD 10.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.51 billion
Estimated Year [2025] USD 7.96 billion
Forecast Year [2030] USD 10.73 billion
CAGR (%) 6.12%

Unveiling the Escalating Challenge of Antibiotic Resistance Across Healthcare Systems and the Critical Imperatives for Stakeholders Worldwide

Healthcare systems around the globe are confronting a mounting crisis as antibiotic resistance accelerates at an unprecedented pace. Pathogens that were once susceptible to standard treatments are evolving mechanisms to evade the once-reliable weapons in our pharmaceutical arsenal. As a result, communities face longer hospital stays, higher medical costs, and a growing mortality burden. In this context, understanding the interplay of scientific innovation, policy reform, and clinical practice has become critical.

Stakeholders across the continuum-from policy-makers to hospital administrators, from research institutions to pharmaceutical executives-must navigate this volatile environment. They require not only real-time visibility into emerging resistance patterns but also a holistic strategy that aligns discovery pipelines with stewardship initiatives. This introductory section lays the groundwork by framing antibiotic resistance as both a public health emergency and a catalyst for transformative industry responses.

Mapping the Transformative Shifts in Antibiotic Development Pipelines Regulatory Frameworks and Global Health Policies Reshaping Therapeutic Strategies and Market Realities

The antibiotic landscape is being reshaped by a confluence of scientific breakthroughs, regulatory recalibrations, and evolving funding mechanisms. In recent years, adaptive trial designs have accelerated candidate screening, while artificial intelligence and machine learning platforms have streamlined target identification and lead optimization. Simultaneously, regulatory bodies have introduced incentives to stimulate development of novel agents, underscoring a paradigm shift toward value-based approval pathways and expedited reviews.

Moreover, collaborations between public institutions, non-profit consortia, and private enterprises are forging new models for risk sharing and resource pooling. These partnerships are fundamental to overcoming the traditional barriers of cost and complexity, especially in late-stage clinical trials where financial exposure can be prohibitive. Accordingly, we are witnessing a strategic realignment in which stakeholder networks are moving beyond transactional alliances to enduring consortiums, thereby distributing both risk and reward more equitably across the antibiotic innovation ecosystem.

At the same time, global health policies are adjusting to the reality that stewardship and access must be balanced. Initiatives aimed at curbing overuse are now being integrated with mechanisms to ensure equitable distribution, particularly in low- and middle-income nations. The result is a more nuanced regulatory environment that demands adaptive commercial strategies and informed advocacy efforts to synchronize market entry with public health objectives.

Assessing the Far-Reaching Consequences of United States Tariff Policies on Antibiotic Supply Chains R&D Investments and Market Accessibility in 2025

United States tariff measures introduced in 2025 have introduced a new variable into the antibiotic supply chain equation. By raising duties on critical intermediates, finished dosage forms, and key raw materials, these policies have cascaded through manufacturing workflows, elevating unit costs and exerting pressure on profit margins. The increased cost base has spurred procurement teams to renegotiate supplier contracts and explore alternative sourcing arrangements, thereby altering entrenched supply-chain relationships.

In parallel, the tariff landscape has prompted multinational companies to reassess their production footprints. Some organizations have initiated feasibility studies to relocate manufacturing closer to end markets or to establish dual-sourcing agreements to mitigate exposure. Consequently, lead times have lengthened for certain molecule classes, introducing variability in inventory cycles and compelling downstream stakeholders to build additional stock buffers to safeguard against potential disruptions.

Perhaps most impactful is the ripple effect on research and development budgets. As companies absorb tariff-related cost increases, discretionary funding for early-stage research faces tighter scrutiny. Projects targeting high-risk pathogen classes may experience reprioritization, while investment committees demand clearer return-on-investment thresholds. This environment compels a recalibration of portfolio strategies, emphasizing asset triage and the pursuit of collaborative funding mechanisms to share developmental costs and expedite time-to-proof of concept.

Deconstructing Market Segmentation Across Drug Classes Pathogen Types Infection Variants and End Use Categories to Illuminate Targeted Opportunities and Strategic Imperatives

A robust segmentation framework illuminates distinct pockets of strategic potential and resistance challenges. Across drug classes, Aminoglycosides exhibit potent bactericidal action against Gram-negative organisms but carry a narrow therapeutic index that necessitates vigilant monitoring. Cephalosporins offer broad-spectrum coverage yet have encountered elevated resistance rates in hospital-acquired infections. Combination Therapies are increasingly favored for their synergistic efficacy against multidrug-resistant strains, while Glycopeptides remain a mainstay for severe Gram-positive infections despite concerns of nephrotoxicity. Oxazolidinones, Sulfonamides, and Tetracyclines each present unique profiles in terms of mechanism of action and safety considerations, prompting tailored stewardship approaches.

On the pathogen front, Acinetobacter baumannii has emerged as a formidable adversary in critical care settings, leveraging adaptive efflux pumps and biofilm formation to thwart intervention. Escherichia coli continues to drive community and hospital onset urinary tract infections, with plasmid-mediated resistance genes proliferating across geographic regions. Klebsiella pneumoniae maintains a high prevalence in ventilator-associated pneumonia, often harboring carbapenemase enzymes that render last-resort treatments ineffective. Pseudomonas aeruginosa's intrinsic resistance coupled with its ability to acquire novel determinants has cemented its status as a priority pathogen. Meanwhile, Staphylococcus aureus and Streptococcus pneumoniae persist as leading causes of both invasive and non-invasive infections, despite decades of targeted vaccine and antibiotic development.

Infection type segmentation reveals that Acute Bacterial Skin & Skin Structure Infections pose a persistent challenge in outpatient and surgical wound contexts, while Bloodstream Infections demand urgent, broad-spectrum coverage to prevent systemic spread. Clostridioides difficile Infection has surged in frequency and severity, prompting focus on narrow-spectrum therapies and microbiome-based interventions. Community-Acquired Bacterial Pneumonia remains a critical driver of hospital admissions, particularly among vulnerable elderly populations, and Complicated Urinary Tract Infections underscore the need for agents with both potent activity and favorable safety profiles.

End-use categories further refine strategic focus. Ambulatory Care Centers are driving demand for oral formulations and outpatient infusion services. Diagnostic Laboratories play an increasingly central role in rapid pathogen identification and susceptibility profiling, accelerating the shift from empirical to precision prescribing. Hospitals & Clinics continue to dominate acute-care utilization, necessitating robust formulary strategies and integrated stewardship protocols. Research Institutes serve as incubators for next-generation modalities, advancing preclinical platforms that may redefine the future of antibiotic discovery.

Delineating Regional Market Dynamics Across the Americas Europe Middle East Africa and Asia Pacific to Highlight Growth Drivers and Emerging Challenges

Regional heterogeneity continues to shape antibiotic resistance dynamics and strategic priorities. In the Americas, well-established regulatory pathways and reimbursement frameworks support the adoption of advanced therapeutic innovations. However, the pervasive use of broad-spectrum agents in outpatient settings has accelerated the emergence of resistant phenotypes, leading to more stringent stewardship guidelines and formulary restrictions. Meanwhile, Latin American markets are grappling with inconsistent supply chains and variable regulatory enforcement, contributing to localized outbreaks of high-risk pathogens.

Across Europe, Middle East & Africa, fragmented healthcare infrastructures and varying levels of access to diagnostic technology complicate coordinated stewardship efforts. In Western Europe, centralized procurement and pan-regional surveillance networks have enabled more cohesive responses to resistance trends. By contrast, emerging markets in the Middle East and Africa face challenges in laboratory capacity, cold-chain logistics, and regulatory alignment, driving reliance on off-patent generics and impeding uptake of novel agents.

Asia-Pacific presents a dual narrative of rapid innovation and persistent public health hurdles. Markets such as Japan, Australia, and South Korea boast sophisticated R&D ecosystems and proactive policy frameworks. At the same time, densely populated regions in Southeast Asia and South Asia experience high rates of antibiotic consumption, often driven by over-the-counter availability and under-resourced stewardship programs. This juxtaposition underscores both the promise of regional leadership in next-generation therapies and the imperative for coordinated cross-border initiatives to curb resistance transmission.

Analyzing Leading Pharmaceutical Players and Emerging Innovators Across Antibiotic R&D and Commercialization to Uncover Competitive Strategies Product Portfolios and Collaborative Networks

A cadre of established pharmaceutical companies continues to anchor the antibiotic market through diversified product portfolios and expansive global reach. These industry leaders prioritize a balanced approach between incremental improvements to existing classes and investments in breakthrough modalities, such as bacteriophage therapies and antimicrobial peptides. Meanwhile, emerging biotechs are carving out niche positions by focusing on precision-targeted mechanisms, leveraging advanced screening platforms to unearth novel scaffolds with reduced propensity for resistance development.

Strategic alliances have become a hallmark of the competitive landscape. Cross-sector partnerships between pharma giants and biotech innovators facilitate agile progression of assets through preclinical validation into early clinical trials. At the same time, consortium models-often supported by government grants and non-profit funding-are aggregating pooled resources to de-risk the development of ultra-narrow-spectrum candidates against priority pathogens.

In the commercialization phase, companies are adopting dynamic pricing and value-based contracting arrangements, linking reimbursement to real-world outcomes data. Such initiatives reflect a growing emphasis on aligning stakeholder incentives to reward both clinical efficacy and responsible utilization. As a result, entities that can demonstrate robust pharmacovigilance mechanisms and post-market surveillance capabilities are gaining a competitive edge, reinforcing the notion that superior product performance extends beyond the laboratory bench.

Formulating Actionable Strategic Recommendations for Industry Leaders to Enhance Antibiotic Stewardship Drive Innovation Strengthen Collaborations and Mitigate Resistance Risks

Industry leaders must adopt a multifaceted strategic playbook to navigate the antibiotic resistance landscape effectively. First, strengthening antimicrobial stewardship programs is paramount; this includes embedding decision-support tools within electronic health records to guide prescribers toward optimal dosing regimens and narrow-spectrum selections. Second, firms should accelerate investment in early-stage discovery platforms, prioritizing novel targets and innovative modalities that circumvent existing resistance mechanisms.

Simultaneously, fostering cross-sector collaboration will amplify impact. Pharmaceutical companies, academic institutions, and non-profit foundations should co-create funding consortia aimed at de-risking high-value projects. By sharing precompetitive data and co-developing clinical trial networks, these alliances can streamline development timelines and distribute financial exposure.

Engagement with regulatory bodies is equally critical. Companies must proactively shape policy dialogues on breakthrough therapy designations, adaptive licensing frameworks, and reimbursement models tied to long-term efficacy data. Clear, evidence-driven advocacy can help align public health objectives with commercial incentives, ensuring that novel agents reach patients without undue delay.

Finally, leveraging real-world evidence and digital health solutions will differentiate market leaders. Telemedicine platforms, rapid diagnostic integration, and post-market surveillance apps can provide granular usage and outcome data. By harnessing these insights, organizations can refine clinical guidelines, demonstrate value to payers, and reinforce responsible prescribing practices across care settings.

Detailing the Rigorous Research Methodology Combining Qualitative Expert Consultations Quantitative Data Analysis and Comprehensive Secondary Research to Ensure Analytical Robustness

This report is underpinned by a rigorous, multi-layered research methodology designed to ensure analytical robustness and factual precision. Primary research comprised in-depth interviews with over 30 senior executives across pharmaceutical companies, clinical microbiologists, policy advisors, and key opinion leaders in infectious disease management. These conversations provided qualitative context around strategic priorities, operational challenges, and market expectations.

Quantitative data collection drew on a wide array of reputable sources, including peer-reviewed journals, regulatory agency publications, hospital procurement records, and patient outcome registries. Data points were meticulously validated through cross-referencing and triangulation to safeguard against bias or inconsistency. In addition, supply chain analytics were integrated to model cost impacts, inventory flows, and lead-time variability under different tariff scenarios.

Secondary research efforts encompassed a comprehensive review of treatment guidelines, policy whitepapers, and global surveillance reports. Special attention was given to emerging regulatory directives and stewardship frameworks, enabling a nuanced understanding of how shifting policies influence both clinical practice and commercial strategy.

Finally, all insights underwent rigorous peer review by an internal panel of domain experts to confirm accuracy, relevance, and forward-looking applicability. This layered approach ensures that conclusions and recommendations are grounded in both empirical evidence and strategic foresight.

Synthesizing Critical Findings on Antibiotic Resistance Escalation Market Transformations and Strategic Pathways to Equip Decision Makers with Clear Insight for Proactive Planning

Antibiotic resistance has transcended a purely clinical concern to become a defining challenge that intersects policy, economics, and public health. The evolving landscape demands that stakeholders adopt integrated strategies, combining innovative research, agile regulatory engagement, and robust stewardship to safeguard the efficacy of existing therapies while accelerating the advent of new ones.

Strategic segmentation by drug class, pathogen type, infection variant, and end use has revealed differentiated areas of focus, guiding targeted investment and commercialization plans. Meanwhile, regional dynamics underscore the need for tailored approaches that reflect local infrastructure, regulatory environments, and cultural prescribing habits. In this complex ecosystem, leading companies are leveraging partnerships, adaptive trial designs, and digital tools to maintain competitive momentum. Looking ahead, the most successful entities will be those that align stakeholder incentives, embrace data-driven decision making, and foster collaborative networks across the public and private sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibiotic Resistance Market, by Offering

  • 8.1. Combination Therapies
  • 8.2. Drugs
    • 8.2.1. Aminoglycosides
    • 8.2.2. Beta-Lactams
    • 8.2.3. Fluoroquinolones
    • 8.2.4. Glycopeptides
    • 8.2.5. Macrolides
    • 8.2.6. Oxazolidinones
    • 8.2.7. Polymyxins
    • 8.2.8. Sulfonamides
    • 8.2.9. Tetracyclines
  • 8.3. Immunomodulators
  • 8.4. Monoclonal Antibodies
  • 8.5. Phage Therapy

9. Antibiotic Resistance Market, by Pathogen Type

  • 9.1. Acinetobacter Paumannii (A. baumannii)
  • 9.2. Escherichia Coli (E. coli)
  • 9.3. Klebsiella Pneumoniae (K. pneumoniae)
  • 9.4. Pseudomonas Aeruginosa (P. aeruginosa)
  • 9.5. Staphylococcus Aureus (S. aureus)
  • 9.6. Streptococcus Pneumonia (S. pneumoniae)

10. Antibiotic Resistance Market, by Infection Type

  • 10.1. Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
  • 10.2. Bloodstream Infections (BSI)
  • 10.3. Clostridioides difficile Infection (CDI)
  • 10.4. Community-Acquired Bacterial Pneumonia (CABP)
  • 10.5. Complicated Urinary Tract Infections (cUTI)

11. Antibiotic Resistance Market, by End Use

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Research Institutes

12. Antibiotic Resistance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antibiotic Resistance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antibiotic Resistance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antibiotic Resistance Market

16. China Antibiotic Resistance Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Basilea Pharmaceutica Ltd
  • 17.8. bioMerieux S.A.
  • 17.9. Cipla Limited
  • 17.10. Cumberland Pharmaceuticals
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. GlaxoSmithKline plc
  • 17.13. Innoviva, Inc.
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. Novo Holdings A/S
  • 17.16. Pfizer Inc.
  • 17.17. Sandoz AG
  • 17.18. Shionogi & Co., Ltd.
  • 17.19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 12. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 146. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 150. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 162. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 163. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 168. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 169. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 170. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 174. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 176. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 180. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)